[Radiation and combination therapy of malignant tumors of the vulva].
The paper is concerned with the results of radiation and multimodality (chemo- and radiotherapy) therapy of patients with malignant vulval tumors. All 112 patients had Stage III-IV disease. A single focal dose was 1.8-2.5 Gy, a summary dose varied from 65 to 100 Gy depending on growth type, tumor histological structure and other factors. Cyclophosphamide, thiotepa, methotrexate and 5-FU were used during simultaneous chemotherapy. Single and summary doses were administered according to an individual program. Drugs reducing local and general radiation reactions were widely used. A direct clinical cure and partial resorption were noted in 109 patients, no effect in 3. The use of various methods of gamma-beam therapy and chemoradiotherapy resulted in the 3-year survival in 51% and the 5-year survival in 18.7% of the patients.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D014846:Vulvar Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
Luchevaia i kompleksnaia terapiia zlokachestvennykh opukholeĭ vul'vy.